Current Treatment of Oligodendrogliomas

Total Page:16

File Type:pdf, Size:1020Kb

Current Treatment of Oligodendrogliomas NEUROLOGICAL REVIEW Current Treatment of Oligodendrogliomas James R. Perry, MD; David N. Louis, MD; J. Gregory Cairncross, MD hat a neurological review is dedicated specifically to the oligodendroglioma is testi- mony to a decade of progress. The unique molecular features and chemosensitivity of the oligodendroglioma were not appreciated 10 years ago; yet today, these features merit such interest to clinicians and pathologists alike that the oligodendroglioma is sepa- Trated from other types of primary brain tumors in both the laboratory and in practice. DIAGNOSIS OF tologically disparate oligodendroglial and OLIGODENDROGLIOMA astrocytic components sharing the same ge- netic alterations. In practice, the distinc- tion of oligodendroglioma from oligoastro- The diagnosis of oligodendroglioma cur- cytoma is probably not as important as the rently rests on standard light micro- distinction between these 2 oligodendrog- scopic assessment of hematoxylin-eosin– lial lesions and pure astrocytoma, since stained slides. Oligodendroglioma cells many oligoastrocytomas, grade for grade, bear some resemblance to oligodendro- behave clinically and respond to both ra- cytes, suggesting that oligodendroglio- diotherapy and chemotherapy in a fashion mas arise from a cell committed to oligo- very similar to pure oligodendrogliomas.1 dendrocytic differentiation. Nonetheless, Furthermore, high-grade oligodendroglio- there are as yet no immunohistochemical mas with perinecrotic pseudopalisading markers to diagnose oligodendroglial neo- should not be equated with typical glioblas- plasms, and attempts to use various mark- tomas; these necrotic oligodendrogliomas ers of oligodendrocytic differentiation have may also be chemosensitive.2 These diag- not proved reliable in tumor sections. Con- nostic difficulties underscore the need to sequently, the pathologist renders a diag- improve the nosological criteria for oligo- nosis of oligodendroglioma based on the dendroglial neoplasms; molecular analy- subjective light microscopic impression of ses may resolve some of the uncertainties, a moderately cellular tumor with regular, since pure and mixed oligodendrogliomas rounded nuclei, sometimes with peri- havecharacteristicpatternsofchromosomal nuclear halos (“fried-egg appearance”) and loss. For instance, combined chromosome sometimes with branching vasculature and 1p and 19q loss is frequently associated with calcifications. oligodendroglial tumors and may therefore The diagnosis is further complicated constitute important adjuncts for diagno- by the fact that many oligodendrogliomas sis of these lesions.3 contain an astrocytic component, which may be substantial at times; such mixed tu- OLIGODENDROGLIOMAS mors are termed oligoastrocytomas. Oli- ARE ONE OF THE MORE goastrocytomas are not “collision” tumors CHEMOSENSITIVE HUMAN SOLID but rather are clonal neoplasms with the his- CANCERS Ten years after Cairncross and Macdonald4 From the Department of Medicine (Neurology), Toronto-Sunnybrook Regional Cancer Center, University of Toronto, Toronto, Ontario (Dr Perry); the Department of first reported remarkable examples of Pathology and the Neurosurgical Service, Molecular Neuro-oncology Laboratory, tumor shrinkage after chemotherapy in pa- Massachusetts General Hospital and Harvard Medical School, Boston (Dr Louis); and tients with recurrent anaplastic oligoden- the Department of Medical Oncology, London Regional Cancer Center, London, droglioma, it is clear that oligodendroglio- Ontario (Dr Cairncross). mas are among the most chemosensitive of ARCH NEUROL / VOL 56, APR 1999 434 ©1999 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/02/2021 all human solid malignancies. While procarbazine, lomus- tein) and the presence of a ring-enhancing tumor con- tine (CCNU), and vincristine sulfate, a chemotherapy regi- ferred significantly worse prognosis. men designated PCV, are most often used in practice, oli- These observations demonstrated for the first time godendrogliomas have been shown to be sensitive to a that specific molecular genetic changes may be used as variety of cytotoxic drugs including melphalan, thio- markers of chemosensitivity in malignant gliomas. Also, tepa, temozolamide, paclitaxel (Taxol), and platinum- these molecular features provided important survival in- based regimens.1,5,6 Response, defined by at least a 50% formation above and beyond traditional prognostic fac- reduction in area of enhancing tumor, is seen in about tors such as age and performance status. A patient whose 75% of patients treated with PCV chemotherapy for anaplastic oligodendroglioma has both 1p and 19q loss recurrent anaplastic oligodendroglioma; many of these would be predicted to show a radiographic response to responses are complete. Responses also have been PCV chemotherapy and have a 5-year survival rate of 95%. shown in patients treated upfront with PCV chemo- A patient with a histologically identical tumor, but with therapy before radiotherapy, patients with both pure CDKN2A deletion, would be less likely to respond to che- and mixed oligodendroglial tumors, and patients with motherapy and have an expected survival of 2 years. Lastly, low-grade oligodendroglioma.1,7 a patient with a ring-enhancing anaplastic oligodendro- The basis of this unique chemosensitivity is un- glioma will probably not respond to chemotherapy and clear; presumably, neoplastic cells in the oligodendrog- have a median survival of less than 1 year despite sur- lial lineage are inherently susceptible to the alkylating gery and radiotherapy. effects of cytotoxic chemotherapy. Low levels of the DNA repair protein O6-methylguanine-DNA methyltransfer- TREATMENT OF LOW-GRADE ase have been found in oligodendroglial cells lines, and OLIGODENDROGLIOMAS Silber et al8 recently observed significantly lower O6- methylguanine-DNA methyltransferase activity in hu- Oligodendrogliomas are classified as low grade if they lack man oligodendrogliomas and mixed glioma samples than or have few histological features suggestive of anapla- in astroglial tumors. Glioma O6-methylguanine-DNA sia: namely, high cellularity, nuclear pleomorphism, mi- methyltransferase levels are also inversely correlated with totic figures, endothelial proliferation, and necrosis. The age, which perhaps explains, at least in part, the well- appropriate management of low-grade oligodendroglio- known survival advantage associated with young age (,45 mas requires individualized consideration, because these years) in patients with malignant glioma. Another in- tumors can be indolently progressive and manifest only triguing hypothesis asserts that, in addition to these as a partial seizure disorder that may often be present for mechanisms, a p53-mediated programmed cell death path- a decade or more; yet, they can also be clinically aggres- way may be activated in oligodendrogliomas after expo- sive and cause a symptomatic, progressively enlarging con- sure to cytotoxic chemotherapy.9 This mechanism may trast-enhancing brain mass. Timing and intensity of post- be similar to observations made in testicular neoplasms; operative therapy is controversial, and it is unclear if oligodendrogliomas rarely harbor p53 gene mutations and patients are best treated at the time of surgical diagnosis frequently display apoptotic tumor cells, yet, like tes- or whether radiotherapy or chemotherapy is best re- ticular cancers, are known to accumulate wild-type p53 served for the time of clinical or radiographic tumor pro- protein. Other authors have suggested that these events gression. At present, nonrandomized retrospective stud- may “prime” the cancer cell to undergo programmed cell ies support maximal feasible surgical resection and death after exposure to chemotherapy.10 Explanations for external-beam radiotherapy when significant residual dis- the chemosensitive nature of oligodendrogliomas await ease is identified on postoperative imaging or when ag- the cloning and characterization of the responsible genes. gressive clinical or pathological features are identified.1 Undoubtedly, radiotherapy is an effective treatment to GENETIC PREDICTORS OF TREATMENT stabilize progressing tumor and to control symptoms such RESPONSE AND SURVIVAL as seizures; however, toxic effects appearing years after cerebral irradiation are a major concern in these pa- Cairncross et al3 recently studied 39 patients with ana- tients because of relatively long survival rates (ie, 80% plastic or aggressive oligodendrogliomas treated with al- at 5 years and 30%-50% at 10 years). It is unclear whether kylating chemotherapy, usually the PCV regimen, who had the tumor-controlling benefits of radiation therapy out- known response and survival outcomes. A variety of clini- weigh its risks in patients with low-grade tumors, al- cal prognostic factors, genetic alterations, and immuno- though it must be stated that radiotherapy is probably histochemical findings were examined in relation to these becoming safer as delivery systems and targeting meth- outcomes. Chromosome 1p loss, found in 70% of cases, ods improve. correlated strikingly with radiological responses to che- There is now a growing body of evidence to sup- motherapy; in fact, 100% of tumors with 1p loss were che- port the notion that low-grade oligodendrogliomas, pure mosensitive. Chromosome 19q loss alone was not asso- or mixed, are chemosensitive. Paleologos et al11 found ciated with response, but the combination of 1p and 19q partial responses in 3 patients and stable responses
Recommended publications
  • Brain Tumors
    BRAIN TUMORS What kinds of brain tumors affect pets? Brain tumors occur relatively often in dogs and cats. The most common type of brain tumor is a meningioma, which originates from the layer surrounding the brain, called the meninges. Meningiomas are slow-growing benign tumors that are often present for months to years before clinical signs appear. Other common types in- clude glial cell tumors, which originate in the brain tissue, and choroid plexus tumors, which originate from the tissue in the brain that produces spinal fluid. Tumors in structures around the brain (like nasal tumors, skull tumors, and pituitary tumors) may also com- press the brain. Lymphoma is a type of cancer that can affect multiple parts of the brain and spine. What are the symptoms? Symptoms vary and depend on the size and location of the tumor. Common signs include changes in behavior, circling or pacing, staring into space, getting stuck in corners, and seizures. Other signs can include weakness, lack of alertness, difficulty eating or swallowing, and problems with the “vestibular system,” or system of bal- ance, such as lack of coordination, head tilt, leaning/circling/falling to one side, and abnormal eye movements. How are brain tumors diagnosed? An MRI scan produces an image of the brain that’s more detailed than a CT scan or x-ray and can identify a tumor. Often the appearance of the tumor on MRI suggests the type of tumor (i.e. meningioma vs lymphoma). However, a biopsy of the tumor is required to give a definitive diagnosis. In some cases, spinal fluid is collected to help diagnose lymphoma.
    [Show full text]
  • Charts Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart
    Charts Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart Glial Tumor Neuronal and Neuronal‐ Ependymomas glial Neoplasms Subependymoma Subependymal Giant (9383/1) Cell Astrocytoma(9384/1) Myyppxopapillar y Desmoplastic Infantile Ependymoma Astrocytoma (9412/1) (9394/1) Chart 1: Benign and Borderline Intracranial and CNS Tumors Chart Glial Tumor Neuronal and Neuronal‐ Ependymomas glial Neoplasms Subependymoma Subependymal Giant (9383/1) Cell Astrocytoma(9384/1) Myyppxopapillar y Desmoplastic Infantile Ependymoma Astrocytoma (9412/1) (9394/1) Use this chart to code histology. The tree is arranged Chart Instructions: Neuroepithelial in descending order. Each branch is a histology group, starting at the top (9503) with the least specific terms and descending into more specific terms. Ependymal Embryonal Pineal Choro id plexus Neuronal and mixed Neuroblastic Glial Oligodendroglial tumors tumors tumors tumors neuronal-glial tumors tumors tumors tumors Pineoblastoma Ependymoma, Choroid plexus Olfactory neuroblastoma Oligodendroglioma NOS (9391) (9362) carcinoma Ganglioglioma, anaplastic (9522) NOS (9450) Oligodendroglioma (9390) (9505 Olfactory neurocytoma Ganglioglioma, malignant (()9521) anaplastic (()9451) Anasplastic ependymoma (9505) Olfactory neuroepithlioma Oligodendroblastoma (9392) (9523) (9460) Papillary ependymoma (9393) Glioma, NOS (9380) Supratentorial primitive Atypical EdEpendymo bltblastoma MdllMedulloep ithliithelioma Medulloblastoma neuroectodermal tumor tetratoid/rhabdoid (9392) (9501) (9470) (PNET) (9473) tumor
    [Show full text]
  • Paraganglioma (PGL) Tumors in Patients with Succinate Dehydrogenase-Related PCC–PGL Syndromes: a Clinicopathological and Molecular Analysis
    T G Papathomas and others Non-PCC/PGL tumors in the SDH 170:1 1–12 Clinical Study deficiency Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC–PGL syndromes: a clinicopathological and molecular analysis Thomas G Papathomas1, Jose Gaal1, Eleonora P M Corssmit2, Lindsey Oudijk1, Esther Korpershoek1, Ketil Heimdal3, Jean-Pierre Bayley4, Hans Morreau5, Marieke van Dooren6, Konstantinos Papaspyrou7, Thomas Schreiner8, Torsten Hansen9, Per Arne Andresen10, David F Restuccia1, Ingrid van Kessel6, Geert J L H van Leenders1, Johan M Kros1, Leendert H J Looijenga1, Leo J Hofland11, Wolf Mann7, Francien H van Nederveen12, Ozgur Mete13,14, Sylvia L Asa13,14, Ronald R de Krijger1,15 and Winand N M Dinjens1 1Department of Pathology, Josephine Nefkens Institute, Erasmus MC, University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands, 2Department of Endocrinology, Leiden University Medical Center, Leiden,The Netherlands, 3Section for Clinical Genetics, Department of Medical Genetics, Oslo University Hospital, Oslo, Norway, 4Department of Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands, 5Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands, 6Department of Clinical Genetics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands, 7Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany, 8Section for Specialized Endocrinology,
    [Show full text]
  • Neuro-Oncology
    Neuro-Oncology Neuro-Oncology 17:iv1–iv62, 2015. doi:10.1093/neuonc/nov189 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012 Quinn T. Ostrom M.A., M.P.H.1,2*, Haley Gittleman M.S.1,2*, Jordonna Fulop R.N.1, Max Liu3, Rachel Blanda4, Courtney Kromer B.A.5, Yingli Wolinsky Ph.D., M.B.A.1,2, Carol Kruchko B.A.2, and Jill S. Barnholtz-Sloan Ph.D.1,2 1Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH USA 2Central Brain Tumor Registry of the United States, Hinsdale, IL USA 3Solon High School, Solon, OH USA 4Georgetown University, Washington D.C. USA 5Case Western Reserve University School of Medicine, Cleveland, OH USA *Contributed equally to this Report. Introduction for collection of central (state) cancer data as mandated in 1992 by Public Law 102-515, the Cancer Registries Amendment The objective of the CBTRUS Statistical Report: Primary Brain and Act.2 This mandate was expanded to include non-malignant Central Nervous System Tumors Diagnosed in the United States brain tumors diagnosed in 2004 and later with the 2002 in 2008-2012 is to provide a comprehensive summary of the passage of Public Law 107–260.3 CBTRUS researchers combine current descriptive epidemiology of primary brain and central the NPCR data with data from the SEER program4 of the NCI, nervous system (CNS) tumors in the United States (US) popula- which was established for national cancer surveillance in the tion. CBTRUS obtained the latest available data on all newly early 1970s.
    [Show full text]
  • Central Neurocytoma SNP Array Analyses, Subtel FISH, and Review
    Pathology - Research and Practice 215 (2019) 152397 Contents lists available at ScienceDirect Pathology - Research and Practice journal homepage: www.elsevier.com/locate/prp Case report Central neurocytoma: SNP array analyses, subtel FISH, and review of the T literature Caroline Sandera,1, Marco Wallenborna,b,1, Vivian Pascal Brandtb, Peter Ahnertc, Vera Reuscheld, ⁎ Christan Eisenlöffele, Wolfgang Kruppa, Jürgen Meixensbergera, Heidrun Hollandb, a Dept. of Neurosurgery, University of Leipzig, Liebigstraße 26, 04103 Leipzig, Germany b Saxonian Incubator for Clinical Translation, University of Leipzig, Philipp-Rosenthal Str. 55, 04103 Leipzig, Germany c Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Haertelstraße 16-18, 04107 Leipzig, Germany d Dept. of Neuroradiology, University of Leipzig, Liebigstraße 22a, 04103 Leipzig, Germany e Dept. of Neuropathology, University of Leipzig, Liebigstraße 26, 04103 Leipzig, Germany ARTICLE INFO ABSTRACT Keywords: The central neurocytoma (CN) is a rare brain tumor with a frequency of 0.1-0.5% of all brain tumors. According Central neurocytoma to the World Health Organization classification, it is a benign grade II tumor with good prognosis. However, Cytogenetics some CN occur as histologically “atypical” variant, combined with increasing proliferation and poor clinical SNP array outcome. Detailed genetic knowledge could be helpful to characterize a potential atypical behavior in CN. Only FISH few publications on genetics of CN exist in the literature. Therefore, we performed cytogenetic analysis of an intraventricular neurocytoma WHO grade II in a 39-year-old male patient by use of genome-wide high-density single nucleotide polymorphism array (SNP array) and subtelomere FISH. Applying these techniques, we could detect known chromosomal aberrations and identified six not previously described chromosomal aberrations, gains of 1p36.33-p36.31, 2q37.1-q37.3, 6q27, 12p13.33-p13.31, 20q13.31-q13.33, and loss of 19p13.3-p12.
    [Show full text]
  • A Case of Mushroom‑Shaped Anaplastic Oligodendroglioma Resembling Meningioma and Arteriovenous Malformation: Inadequacies of Diagnostic Imaging
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 10: 1499-1502, 2015 A case of mushroom‑shaped anaplastic oligodendroglioma resembling meningioma and arteriovenous malformation: Inadequacies of diagnostic imaging YAOLING LIU1,2, KANG YANG1, XU SUN1, XINYU LI1, MINGHAI WEI1, XIANG'EN SHI2, NINGWEI CHE1 and JIAN YIN1 1Department of Neurosurgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116044; 2Department of Neurosurgery, Affiliated Fuxing Hospital, The Capital University of Medical Sciences, Beijing 100038, P.R. China Received December 29, 2014; Accepted June 29, 2015 DOI: 10.3892/etm.2015.2676 Abstract. Magnetic resonance imaging (MRI) is the most tomas (WHO IV) (2). The median survival times of patients widely discussed and clinically employed method for the with WHO II and WHO III oligodendrogliomas are 9.8 and differential diagnosis of oligodendrogliomas; however, 3.9 years, respectively (1,2), and 6.3 and 2.8 years, respec- MRI occasionally produces unclear results that can hinder tively, if mixed with astrocytes (3,4). Surgical excision and a definitive oligodendroglioma diagnosis. The present study postoperative adjuvant radiotherapy is the traditional therapy describes the case of a 34-year-old man that suffered from for oligodendroglioma; however, studies have observed that, headache and right upper‑extremity weakness for 2 months. among intracranial tumors, anaplastic oligodendrogliomas Based on the presurgical evaluation, it was suggested that the are particularly sensitive to chemotherapy, and the prognosis patient had a World Health Organization (WHO) grade II-II of patients treated with chemotherapy is more favorable glioma, meningioma or arteriovenous malformation (AVM), than that of patients treated with radiotherapy (5‑7).
    [Show full text]
  • Brain Invasion in Meningioma—A Prognostic Potential Worth Exploring
    cancers Review Brain Invasion in Meningioma—A Prognostic Potential Worth Exploring Felix Behling 1,2,* , Johann-Martin Hempel 2,3 and Jens Schittenhelm 2,4 1 Department of Neurosurgery, University Hospital Tübingen, Eberhard-Karls-University Tübingen, 72076 Tübingen, Germany 2 Center for CNS Tumors, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard-Karls-University Tübingen, 72076 Tübingen, Germany; [email protected] (J.-M.H.); [email protected] (J.S.) 3 Department of Diagnostic and Interventional Neuroradiology, University Hospital Tübingen, Eberhard-Karls-University Tübingen, 72076 Tübingen, Germany 4 Department of Neuropathology, University Hospital Tübingen, Eberhard-Karls-University Tübingen, 72076 Tübingen, Germany * Correspondence: [email protected] Simple Summary: Meningiomas are benign tumors of the meninges and represent the most common primary brain tumor. Most tumors can be cured by surgical excision or stabilized by radiation therapy. However, recurrent cases are difficult to treat and alternatives to surgery and radiation are lacking. Therefore, a reliable prognostic marker is important for early identification of patients at risk. The presence of infiltrative growth of meningioma cells into central nervous system tissue has been identified as a negative prognostic factor and was therefore included in the latest WHO classification for CNS tumors. Since then, the clinical impact of CNS invasion has been questioned by different retrospective studies and its removal from the WHO classification has been suggested. Citation: Behling, F.; Hempel, J.-M.; There may be several reasons for the emergence of conflicting results on this matter, which are Schittenhelm, J. Brain Invasion in discussed in this review together with the potential and future perspectives of the role of CNS Meningioma—A Prognostic Potential invasion in meningiomas.
    [Show full text]
  • What Are Brain and Spinal Cord Tumors in Children? ● Types of Brain and Spinal Cord Tumors in Children
    cancer.org | 1.800.227.2345 About Brain and Spinal Cord Tumors in Children Overview and Types If your child has just been diagnosed with brain or spinal cord tumors or you are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Are Brain and Spinal Cord Tumors in Children? ● Types of Brain and Spinal Cord Tumors in Children Research and Statistics See the latest estimates for new cases of brain and spinal cord tumors in children in the US and what research is currently being done. ● Key Statistics for Brain and Spinal Cord Tumors in Children ● What’s New in Research for Childhood Brain and Spinal Cord Tumors? What Are Brain and Spinal Cord Tumors in Children? Brain and spinal cord tumors are masses of abnormal cells in the brain or spinal cord 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 that have grown out of control. Are brain and spinal cord tumors cancer? In most other parts of the body, there's an important difference between benign (non- cancerous) tumors and malignant tumors (cancers1). Benign tumors do not invade nearby tissues or spread to distant areas, and are almost never life threatening in other parts of the body. Malignant tumors (cancers) are so dangerous mainly because they can spread throughout the body. Brain tumors rarely spread to other parts of the body, though many of them are considered malignant because they can spread through the brain and spinal cord tissue. But even so-called benign tumors can press on and destroy normal brain tissue as they grow, which can lead to serious or sometimes even life-threatening damage.
    [Show full text]
  • The New WHO Classification of Brain Tumors and Molecular Profiling in the Diagnosis of Gliomas
    The New WHO Classification of Brain Tumors and Molecular Profiling in the Diagnosis of Gliomas Aivi Nguyen, MD Neuropathology Fellow Division of Neuropathology Center for Personalized Diagnosis (CPD) Glial neoplasms – infiltrating gliomas Astrocytic tumors • Diffuse astrocytoma II • Anaplastic astrocytoma III • Glioblastoma • Giant cell glioblastoma IV • Gliosarcoma Oligodendroglial tumors • Oligodendroglioma II • Anaplastic oligodendroglioma III Oligoastrocytic tumors • Oligoastrocytoma II • Anaplastic oligoastrocytoma III Courtesy of Dr. Maria Martinez-Lage 2 2016 3 The 2016 WHO classification of tumours of the central nervous system Louis et al., Acta Neuropathologica 2016 4 Talk Outline Genetic, epigenetic and metabolic changes in gliomas • Mechanisms/tumor biology • Incorporation into daily practice and WHO classification Penn’s Center for Personalized Diagnostics • Tests performed • Results and observations to date Summary 5 The 2016 WHO classification of tumours of the central nervous system Louis et al., Acta Neuropathologica 2016 6 Mechanism of concurrent 1p and 19q chromosome loss in oligodendroglioma lost FUBP1 CIC Whole-arm translocation Griffin et al., Journal of Neuropathology and Experimental Neurology 2006 7 Oligodendroglioma: 1p19q co-deletion Since the 1990s Diagnostic Prognostic Predictive Li et al., Int J Clin Exp Pathol 2014 8 Mutations of Selected Genes in Glioma Subtypes GBM Astrocytoma Oligodendroglioma Oligoastrocytoma Killela et al., PNAS 2013 9 Escaping Senescence Telomerase reverse transcriptase gene
    [Show full text]
  • Malignant CNS Solid Tumor Rules
    Malignant CNS and Peripheral Nerves Equivalent Terms and Definitions C470-C479, C700, C701, C709, C710-C719, C720-C725, C728, C729, C751-C753 (Excludes lymphoma and leukemia M9590 – M9992 and Kaposi sarcoma M9140) Introduction Note 1: This section includes the following primary sites: Peripheral nerves C470-C479; cerebral meninges C700; spinal meninges C701; meninges NOS C709; brain C710-C719; spinal cord C720; cauda equina C721; olfactory nerve C722; optic nerve C723; acoustic nerve C724; cranial nerve NOS C725; overlapping lesion of brain and central nervous system C728; nervous system NOS C729; pituitary gland C751; craniopharyngeal duct C752; pineal gland C753. Note 2: Non-malignant intracranial and CNS tumors have a separate set of rules. Note 3: 2007 MPH Rules and 2018 Solid Tumor Rules are used based on date of diagnosis. • Tumors diagnosed 01/01/2007 through 12/31/2017: Use 2007 MPH Rules • Tumors diagnosed 01/01/2018 and later: Use 2018 Solid Tumor Rules • The original tumor diagnosed before 1/1/2018 and a subsequent tumor diagnosed 1/1/2018 or later in the same primary site: Use the 2018 Solid Tumor Rules. Note 4: There must be a histologic, cytologic, radiographic, or clinical diagnosis of a malignant neoplasm /3. Note 5: Tumors from a number of primary sites metastasize to the brain. Do not use these rules for tumors described as metastases; report metastatic tumors using the rules for that primary site. Note 6: Pilocytic astrocytoma/juvenile pilocytic astrocytoma is reportable in North America as a malignant neoplasm 9421/3. • See the Non-malignant CNS Rules when the primary site is optic nerve and the diagnosis is either optic glioma or pilocytic astrocytoma.
    [Show full text]
  • Meningioma ACKNOWLEDGEMENTS
    AMERICAN BRAIN TUMOR ASSOCIATION Meningioma ACKNOWLEDGEMENTS ABOUT THE AMERICAN BRAIN TUMOR ASSOCIATION Meningioma Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit advocacy organization dedicated solely to brain tumor research. For nearly 45 years, the ABTA has been providing comprehensive resources that support the complex needs of brain tumor patients and caregivers, as well as the critical funding of research in the pursuit of breakthroughs in brain tumor diagnosis, treatment and care. To learn more about the ABTA, visit www.abta.org. We gratefully acknowledge Santosh Kesari, MD, PhD, FANA, FAAN chair of department of translational neuro- oncology and neurotherapeutics, and Marlon Saria, MSN, RN, AOCNS®, FAAN clinical nurse specialist, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA; and Albert Lai, MD, PhD, assistant clinical professor, Adult Brain Tumors, UCLA Neuro-Oncology Program, for their review of this edition of this publication. This publication is not intended as a substitute for professional medical advice and does not provide advice on treatments or conditions for individual patients. All health and treatment decisions must be made in consultation with your physician(s), utilizing your specific medical information. Inclusion in this publication is not a recommendation of any product, treatment, physician or hospital. COPYRIGHT © 2017 ABTA REPRODUCTION WITHOUT PRIOR WRITTEN PERMISSION IS PROHIBITED AMERICAN BRAIN TUMOR ASSOCIATION Meningioma INTRODUCTION Although meningiomas are considered a type of primary brain tumor, they do not grow from brain tissue itself, but instead arise from the meninges, three thin layers of tissue covering the brain and spinal cord.
    [Show full text]
  • Recent Advances in the Treatment of Gliomas – Comprehensive Brain Tumor Center
    RECENT ADVANCES IN NEUROSURGERY Recent Advances in the Treatment of Gliomas – Comprehensive Brain Tumor Center STEVEN A. TOMS, MD, MPH; NIKOLAOS TAPINOS, MD, PhD ABSTRACT development of electric current loco-regional antimitotic Gliomas are a class of primary brain tumors arising from therapy (“tumor-treating fields”) led to the first reported the supporting structures of the brain, the astrocytes and survivals exceeding 20 months7. oligodendrocytes, which range from benign lesions to In the United States alone, 12,000 new cases of GBM are its most malignant form, the glioblastoma. Treatment diagnosed each year8. One reason cited for the failure to for these lesions includes maximal surgical resection, improve survival has been the presence of a robust blood- radiotherapy, and chemotherapy. Recently, novel thera- brain barrier within the tumor, which impedes delivery of pies such as immune modulatory therapies and electrical traditional cytotoxic and novel molecular therapies9. Most field treatment of the most malignant form, the glioblas- chemotherapeutic agents are hydrophilic, and do not pene- toma, have shown promise in improving survival. We trate the blood brain barrier well. Attempts to deliver che- will review recent advances in clinical trials, explore the motherapeutic molecules into the brain have included both role of multimodal care in brain tumor therapy, as well osmotic, chemical, and ultrasound mediated opening of the as explore advances in molecular biology and nanotech- blood brain barrier to improve drug delivery, but none have nology which offer new hope for treatment of this class improved clinical outcomes10. A novel method to bypass of disease. this barrier, (i.e., convection enhanced delivery), met with KEYWORDS: glioblastoma, immunotherapy, tumor success in delivering high drug concentrations of hydro- treating fields, nanotechnology, drug delivery philic drugs to brain tumors and led to several clinical trials.
    [Show full text]